Objectives: Heat shock protein 90 regulates multiple signaling proteins involved in key pathways of pancreatic cancer pathogenesis. Ganetespib binds to heat shock protein 90 and interferes with its binding to client proteins thus leading to inactivation and degradation of the signaling proteins that promote cancer progression. This phase II study was designed to evaluate the efficacy of ganetespib in patients with refractory metastatic pancreatic cancer (rMPC).
P
ancreas adenocarcinoma (hereafter referred to as pancreatic cancer) is one of the most lethal of all human malignancies, and is currently the 4th leading cause of cancer death in the United States. 1 Pancreatic cancer is a highly resistant and aggressive neoplasm with a dismal five-year survival rate of <5%. 2 Several treatment strategies have been explored with limited success. For decades, gemcitabine has been the only chemotherapy drug available for treatment of advanced pancreatic cancer patients. Recently, therapeutic combinations of gemcitabine with erlotinib or nab-paclitaxel, as well as the nongemcitabine combination of 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan, including the nanoliposomal irinotecan, have shown some promising clinical activity [3] [4] [5] [6] [7] ; however, the median overall survival (OS) of patients with advanced pancreatic cancer remains B1 year, 8, 9 and the 5-year survival rate is <10%. 10 Thus, the need for effective systemic therapy is great in this patient population.
Novel agents that specifically target cellular processes or pathways have gained interest as potential treatments to effectively halt at least some of the aberrant signaling pathways that are crucial in pathogenesis of pancreatic cancer. 11 Heat shock proteins (HSPs) are a class of molecular chaperone proteins that help modulate cellular responses to environmental stress. Chaperones are important for normal cellular functions, but in tissues subject to external stressors, for example, hypoxia or acidosis, these HSPs are expressed at higher levels thus aiding cell survival. In particular, HSP90 regulates the folding, stability, and function of signaling proteins such as B-RAF, c-KIT, c-MET, EGFR, HER2, and PDGFRA. 12 Given the diversity of currently identified HSP90 client proteins, many of which are known to be critical regulators of cancer cell proliferation and survival, 12 HSP90 inhibitors would be expected to show activity against a wide variety of human tumor types. Preclinical studies have revealed potent HSP90 inhibition and activity against a range of models including lung, prostate, colon, breast, melanoma, and leukemia. [13] [14] [15] [16] [17] [18] Furthermore, early clinical trials with HSP90 inhibitors have demonstrated responses in several types of cancer supporting the importance of HSP90 as a potential therapeutic target. [19] [20] [21] Ganetespib (STA-9090) is a second-generation small molecule inhibitor of HSP90, and is currently in clinical trials for a number of human cancers. 22 Ganetespib has a novel chemical structure, unlike geldanamycin, 23 with a resorcinolcontaining triazole compound that binds to the adenosine triphosphate pocket in the N-terminus of HSP90. It prevents HSP90 from binding to client proteins thus leading to inactivation and disruption of cell signaling networks that promote cancer progression. In vitro and in vivo data show promising results from both a biochemical standpoint in altering the expression of key proteins important for the machinery of the cell, as well as from a purely cytotoxic standpoint. 24, 25 Treatment of bone marrow-derived cultured mast cells, malignant mast cell lines, and fresh malignant cells with ganetespib induced growth inhibition, caspase 3/7-dependent apoptosis, and downregulation of the total and phosphorylated Kit and AKT. 25 In non-small cell lung cancer cells and xenograft models, ganetespib effectively destabilized a number of oncogenic drivers, thereby inactivating downstream mitogenactivated protein kinase and AKT signaling to induce apoptosis. 26 In the first-in-human phase I trial of patients with solid tumors, single-agent ganetespib administered once weekly had an acceptable toxicity profile and showed some clinical activity with 1 partial response (PR) and a substantial number (45.3%) of patients with durable stable disease (SD). 19 Given that pharmacologic inhibition of HSP90 resulted in a marked decrease of the proliferative activity in pancreatic cell lines and suppression of pancreatic xenograft growth 27, 28 in combination with the observed clinical activity of the HSP90 inhibitor ganetespib, we designed a phase II study to evaluate the efficacy of ganetespib in patients with advanced pancreatic cancer who have failed 1 or 2 lines of previous therapy. An unmet clinical need exists as few therapeutic options are available for this group of patients.
PATIENTS AND METHODS

Study Design
We conducted a 2-center clinical trial sponsored by the Vanderbilt-Ingram Cancer Center support grant (P30CA68485) and Synta Pharmaceuticals (clinicaltrials.gov identifier NCT 01227018). The protocol was approved at the Institutional Review Boards of the participating institutions, and written informed consent was obtained for all patients before performing study-related procedures in accordance with federal and institutional guidelines. Patients were enrolled at the Vanderbilt-Ingram Cancer Center and at the Jones Clinic. This is a nonrandomized, open-label, single arm study conducted at 2 centers in patients with metastatic refractory pancreatic cancer. The primary objective was to measure the 8-week disease control rate (DCR) of ganetespib in patients with metastatic pancreatic cancer who have failed (either progressed or did not tolerate) 1 or 2 lines of prior therapy. DCR is defined as the ratio of the number of patients who achieve a complete response (CR), PR, or SD to the total number of patients enrolled on study. Our study goal was to achieve a DCR of 70% or better after 8 weeks of therapy based on historical control data and preliminary data from the CONKO-003 trial presented at the 2008 ASCO annual meeting. 29 Secondary objectives were to determine response rate, OS, and toxicity profile.
Eligibility Criteria
Eligible patients had pathologically confirmed metastatic pancreatic cancer, had received 1 or 2 prior chemotherapy regimens for metastatic disease, and were Z18 years of age with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Adequate organ (hematologic, renal, and hepatic) function and ventricular ejection fraction (Z55%) were required. The patients who received adjuvant or neoadjuvant therapy were also eligible if they had progressed within 6 months of completing therapy and had not received a metastatic regimen, or if they progressed >6 months after completing therapy and have received 1 or 2 lines of therapy for metastatic disease. Clinically and radiologically stable brain metastases were allowed.
Patients were excluded for any of the following: a major surgery or use of any investigational agent within 4 weeks before entering the study; pregnant or lactating women; treatment with chronic immune suppressants (eg, cyclosporine following transplantation or systemic steroids for treatment of autoimmune disease); uncontrolled central nervous system metastases; New York Heart Association class III/IV congestive heart failure requiring active treatment; active coronary artery disease, myocardial infarction, angina pectoris, angioplasty, or coronary bypass surgery within 6 months of study registration; ventricular arrhythmia requiring antiarrhythmic agents; grade 2 or greater left bundle branch block; baseline corrected QT interval of >470 ms; patients with uncontrolled illness/active infection including HIV-positive subjects receiving combination antiretroviral therapy; severe acute/chronic psychiatric condition; or laboratory abnormality that might interfere with study drug administration or with the interpretation of study results in the judgment of the investigator.
Study Treatment
All patients were treated with 175 mg/m 2 of ganetespib once weekly by a 60-minute intravenous infusion for three consecutive weeks followed by a 1-week dose-free interval in 4-week cycles. Dose delays and reductions were permitted for grade 2 or 3 ganetespib-related toxicities. Treatment with ganetespib continued until disease progression, unacceptable toxicity, or patient withdrawal.
Study Assessments
Patient demographics and medical history were recorded at baseline. Safety assessments were conducted at baseline and weekly during treatment. An electrocardiogram was conducted at baseline, as well as at predose and postdose (within 1 hour) on day 1 of each cycle to evaluate for corrected QT prolongation. Adverse events (AEs) were assessed at baseline and weekly during treatment, and toxicity was graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0. Clinical activity was assessed by computed tomography scans at baseline and every 8 weeks thereafter while on the study. Tumor responses were categorized per Response Evaluation Criteria in solid Tumors (RECIST) version 1.1. Participants who had measureable disease at baseline and received at least 1 dose of therapy were considered evaluable for response. Patients who were unable to have their disease reevaluated or did not return for follow-up were considered nonresponders.
Statistical Analysis
The sample size calculation was based on a standard Simon's optimal 2-stage design. Given historical control data as well as the preliminary results of the CONKO-003 trial, 29 we would consider ganetespib insufficiently active if it elicits a true 8-week DCR of 50%. In the first stage, 15 patients were entered in the study. If 8 or fewer patients among the first 15 treated achieved a DCR (CR + PR + SD) at 8 weeks after treatment, the study would be closed. Otherwise, additional patients would be accrued to a maximum size of 43 patients. Ganetespib was considered sufficiently active to warrant further study in more definitive clinical trials if 27 or more patients demonstrated disease control at 8 weeks. If a low 8-week DCR (eg, 50%) was noted, the expected sample size was 24 patients with a 70% probability of early termination. The study design had a 5% type I error rate of incorrectly declaring promising activity if the true DCR at 8 weeks was <50%, and 80% probability (power) of declaring sufficient activity if the true DCR at 8 weeks was >70%.
RESULTS
Patients and Treatment
The characteristics of eligible patients are summarized in Table 1 . Between January 2011 and November 2012, 15 patients were enrolled into the study; however, 1 patient did not receive study drug due to active disease progression before treatment initiation. The median age was 65 (range, 33 to 77), and a majority of the patients were male (73.3%) and had a performance status of 1 (79%). Eight patients had received 1 line of therapy, whereas the other 6 patients received 2 prior lines of therapy for their disease.
Clinical Activity
Among the 15 patients enrolled, 9 patients came off study due to radiographic disease progression, 2 patients were removed from the study based on unacceptable toxicity, and 4 patients decided to withdraw from the study based on reasons other than protocol-defined toxicity or progression. Clinical response was not evaluable in 1 patient who experience disease progression before initiating treatment. Two patients did not return to have their disease reevaluated after starting therapy, and therefore these patients were considered nonresponders. No documented CRs or PRs were observed, however 3 patients (21.4%) achieved a best response of SD. The overall DCR at 8 weeks was 28.6% (95% confidence interval [CI], 11.7%-54.6%). Because of lack of efficacy in the interim analysis, the trial was stopped. The median progression-free and OS was 1.58 months (95% CI, 1.15-4.7 mo) and 4.57 months (95% CI, 3.25-11.8 mo), respectively (Fig. 1) . The median number of treatment cycles for all patients was 1.4 (range, 0.5-3.7).
Toxicity
Among the 14 patients evaluated for safety, 13 (86.7%) reported toxicities related to study treatment; 1 patient did not experience a toxicity related to the study drug. The most common (frequency >20%) AEs were diarrhea, fatigue, nausea, abdominal pain, anorexia, constipation, vomiting, elevated alanine aminotransferase, aspartate aminotransferase, anaplastic lymphoma kinase, and blood bilirubin, lymphopenia, and thrombocytopenia ( Table 2 ). The majority of these observed events were grade 1 or 2; however, 7 patients experienced grade 3 toxicities, including diarrhea (n = 4), abdominal pain (n = 1), nausea (n = 1), vomiting (n = 1), fatigue (n = 2), and hyponatremia (n = 1). No instances of ganetespibrelated visual disturbances were reported. In addition, no grade 4 or 5 treatment-related events were reported. A total of 4 patients (28.6%) required dose modifications due to AEs; 3 patients had at least 1 dose omission, whereas 1 patient had both a dose omission and reduction during treatment.
DISCUSSION
Several studies have observed high levels of HSP90 mRNA among pancreatic carcinoma tumor samples, [30] [31] [32] and pharmacologic inhibition of HSP90 resulted in antitumor activity in vivo. 27, 28 In addition, several HSP90 client proteins have been shown to be important in pancreatic cancer initiation, progression, and maintenance. 12 Therefore, therapies directed toward inhibition of HSP90 could simultaneously disrupt multiple key oncogenic proteins, and thus have emerged as potential treatment strategies for pancreatic cancer. 33 Ganetespib is one HSP90 inhibitor that has gained recent interest in the treatment of solid tumors. In phase I and II trials, ganetespib demonstrated a favorable safety profile in patients with refractory metastatic or locally advanced solid tumors with some hint of efficacy. 19, 34 On the basis of these results, we designed the current phase II study with the hypothesis that inhibition of HSP90 with ganetespib monotherapy would be safe and efficacious in patients with pancreatic cancer.
To the best of our knowledge, this was the first study to investigate single-agent ganetespib in the treatment of patients with metastatic pancreatic cancer who have progressed following 1 or 2 lines of previous therapy. Ganetespib monotherapy was well tolerated with minimal AEs. Most of the treatment-related toxicities were grade 1 or 2 and no treatmentrelated deaths were observed. The primary study endpoint was DCR after 8 weeks of therapy, which was 28.6%. On the basis of the planned interim analysis, this study was terminated early due to lack of prespecified clinical efficacy. It is important to mention, however, that the patients included in this trial were heavily pretreated who received ganetespib as a second-line or third-line therapy.
Ganetespib as a monotherapy has also been investigated in additional cancers, including hepatocellular carcinoma, 35 metastatic breast cancer, 20 and non-small cell lung cancer 21 ; however, similar to the current study, limited clinical benefit in these patient populations was observed. Because of the limited efficacy as a single-agent therapy, numerous ongoing clinical trials are investigating ganetespib in combination with a variety of chemotherapeutic and targeted agents. Two recent studies investigating ganetespib combination therapies observed acceptable toxicity profiles and encouraging efficacy data in the treatment of rectal 36 and lung 37 cancers. In the phase II GALAXY-1 trial, ganetespib was investigated in combination with docetaxel as a second-line therapy in advanced non-small cell lung cancer; however, the combination therapy failed to improve progressionfree survival. 38 Nonetheless, a trend in clinical benefit was observed in a subgroup of patients with adenocarcinoma that were diagnosed with advanced disease >6 months before study entry; these results led to the design of the phase III GALAXY-2 trial for patients of that subgroup. Despite the trend in the phase II trial, the phase III trial closed early for futility. Although ganetespib plus docetaxel failed in lung cancer, combination therapies are still under investigation in ovarian (NCT02012192) and breast (NCT01042379) cancer, as well as acute myeloid leukemia and high-risk myelodysplastic syndrome (NCT01236144).
Although clinical trials investigating ganetespib treatment combinations have been performed in a variety of other cancers, combination regimens in pancreatic cancer have not been tested. Nagaraju et al recently investigated ganetespib in combination with 5-fluorouracil and oxaliplatin in pancreatic tumor xenografts and observed a significant increase in tumor growth inhibition with the triplet combination compared with ganetespib or oxaliplatin/5-fluorouracil thereby providing evidence to suggest that ganetespib enhances the activity of chemotherapy in pancreatic cancer. 39 These results, therefore, provide motivation for investigating ganetespib-containing combination regimens in the treatment of advanced malignancies such as pancreatic cancer. In conclusion, ganetespib had an acceptable toxicity profile with modest clinical activity in patients with previously treated advanced pancreatic cancer. However, given the absence of tumor response and the limited activity when given as a monotherapy, ganetespib in combination with other cytotoxic chemotherapies should be investigated. 
